Lilly to Acquire Orna Therapeutics to Advance Cell Therapies

Eli Lilly makes $2.4B bet on RNA tech

The acquisition of Orna Therapeutics signals rising confidence in RNA medicines.

Lilly strikes again, buying CAR-T firm Orna for $2.4bn

In its second major deal in two days, Eli Lilly has reached an agreement to buy in vivo CAR-T developer Orna Therapeutics for up to $2.4bn.

Lilly buys ‘in vivo’ CAR-T maker Orna, extending streak of genetic medicine deals

Worth up to $2.4 billion, the acquisition is also the latest in a series of buyouts involving startups with technologies that modify immune cells inside the body.

Eli Lilly to buy Orna Therapeutics for $2.4 billion

Eli Lilly will pay up to $2.4 billion for the biotechnology firm, the latest in a string of deals that the pharmaceutical giant has made in the past year.

Lilly to acquire Orna Therapeutics to advance cell therapies

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today...

Lilly to acquire Orna Therapeutics for $2.4 billion - CEO North America

Eli Lilly and Company announced today that it has entered into a definitive agreement to acquire Orna Therapeutics, Inc. for up to $2.4 billion in cash. The deal aims to advance cell therapies and help address the complexity and cost of delivering these breakthroughs to the broader patient population. Under the agreement, Orna shareholders may receive up to $2.4 billion in cash, including an upfront payment and additional payments upon achieveme…